Med Ed Report briefs: October 2012

Harold Magazine
Harold Magazine

As of July, 26 major companies and nine of the top 10 global drugmakers were under corporate integrity agreements, Boston University law professor Kevin Outterson wrote in an NEJM op-ed, noting that rather than piecemeal measures, legislators should consider tougher laws to deter corporate misbehavior.

The MedBiquitous standards consortium is supporting FDA's REMS initiative for ER/LA opioids by enabling data about compliant CE programs from across the health professions to be aggregated.

Physicians' Education Resource (PER), an accredited CME provider, named Harold Magazine, PhD, as president. PER also named Alexis A.M. Mascitti, MD, as the company's VP of scientific affairs.

CECity said it launched a cloud-based “learning health system” platform to Blue Cross Blue Shield executives from across the country at their 2012 Blue National Summit.

CBI's 14th Annual Forum on Off-Label Guidelines is set for October 11–12 at the Doubletree Hotel Center City in Philadelphia. It's intended to help companies ensure their medical and promotional information complies with off-label regulations.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.